Physician profile
Matthew Ormond
NPI 1952870545
$5,971.14
in general payments reported to CMS, 2019-2025
33 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,773 · 2022: $925 · 2023: $1,125 · 2024: $771 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,801.38 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,039.28 | 2021 | |
| Amarin Pharma, INC. | $767.05 | 2021-2023 | |
| Harmony Biosciences LLC | $324.76 | 2021-2024 | |
| Corium, LLC | $280.45 | 2022-2023 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $195.68 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $190.59 | 2022-2024 | Austedo Xr, Ajovy |
| Lilly USA, LLC | $177.73 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $139.14 | 2021-2024 | Repatha, Otezla |
| Ironshore Pharmaceuticals INC. | $96.83 | 2023-2024 | Jornay Pm |
| Pfizer INC. | $96.55 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.25 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $85.63 | 2022-2024 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $85.14 | 2023 | Zeposia |
| Astellas Pharma US INC | $71.23 | 2023-2024 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $49.18 | 2021 | |
| Shield Therapeutics INC | $48.08 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.03 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $40.90 | 2021-2022 | |
| Axsome Therapeutics, INC. | $40.34 | 2025 | Auvelity |
| Novo Nordisk INC | $34.93 | 2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $34.53 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $33.17 | 2023 | Quviviq |
| Dexcom, INC. | $30.10 | 2021-2024 | Dexcom G6 Transmitter |
| Photonicare INC | $22.32 | 2025 | Otosight Middle Ear Scope |
| Medtronic, INC. | $21.32 | 2021 | |
| Exact Sciences Corporation | $20.84 | 2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $19.85 | 2021 | |
| Cipher Pharmaceuticals US LLC | $19.41 | 2025 | Natroba, Spinosad |
| Phadia US INC. | $18.12 | 2023 | Immunocap |
| Sanofi Pasteur INC. | $17.23 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.43 | 2022 | |
| Indivior INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ormond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.